TG Therapeutics recently initiated an open-label Phase 2 trial of BRIUMVI (ublituximab-xiiy) in about 60 adults with ...

The collaboration will bring Cortechs.ai's quantitative MRI analysis into Viz.ai's care coordination platform, beginning with ...

New diagnostic criteria for multiple sclerosis are helping doctors identify the disease sooner, allowing patients to begin ...

Dr. Daniel Ontaneda, a neurologist with Cleveland Clinic, said more than two dozen approved medications can help control MS ...

Earlier diagnostic options for MS are now possible, Zyn nicotine pouches get an FDA risk claim, and norovirus concerns rise.

According to the latest market analysis by Future Market Insights, the global B-Cell Depletion Therapy Market is projected to ...

Our latest CPD module explores five common but challenging neurology cases encountered in general practice, and discusses evidence-based approaches to assessment, investigation and management.

Dysphagia, a severe comorbidity of many neurological diseases, often lacks targeted therapies. This critical review assessed ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

True disruption demands both vision and courage, and these ten remarkable women are leading that charge in 2026.

The plan's most telling feature is what it left out. Two months before the announcement, Pfizer and Valneva reported that their Lyme vaccine had passed its final major trial, cutting confirmed cases ...